

VABYSMO ADMINISTRATION GUIDE

Optimal withdrawal technique ensures your patients receive the full VABYSMO experience

Selected steps for VABYSMO preparation for administration: Read all the instructions carefully from the VABYSMO Prescribing Information before using VABYSMO.

Room Temp: 20°C to 25°C

Once the vial reaches room temperature, place it on a flat surface for about 1 min.



Gently tap vial with your finger, as liquid may stick to top of vial. Remove cap, wipe vial septum with alcohol, and aseptically attach *included* filter needle onto 1 mL Luer lock syringe.



After **firmly pushing** filter needle all the way into center using aseptic technique, **tilt vial slightly** so needle touches bottom edge of vial.



Keeping vial slightly tilted and bevel of needle submerged (to avoid introduction of air), slowly withdraw all liquid.

Check that the plunger rod is drawn sufficiently back when emptying the vial **to ensure the filter needle is emptied completely.** Then dispose of the filter needle.

After this, aseptically attach a 30-gauge x ½ inch injection needle onto Luer lock syringe.

Gently tap the syringe with your finger to clear any air bubbles.

Carefully expel the air from the syringe and needle. Then make sure to **slowly depress the plunger** to align the rubber stopper tip to the **0.05 mL dose mark.** Now the syringe is ready for injection. Ensure the injection is given immediately after preparing the dose. Refer to the Prescribing Information for injection procedure.





VABYSMO ADMINISTRATION GUIDE

EACH VABYSMO KIT CONTAINS

- Single dose vial of VABYSMO
- 5-micron blunt transfer filter needle,18-gauge x 1.5 inch (1.2 mm x 40 mm)

NOT INCLUDED IN THE KIT





1 mL Luer lock syringe with 0.05 mL dose mark

30-gauge x 0.5 inch (13 mm) injection needle*

*Smaller diameter needles are not recommended. These may cause increased injection forces.

INDICATIONS

VABYSMO (faricimab) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).

.

IMPORTANT SAFETY INFORMATION

Contraindications

VABYSMO is contraindicated in patients with ocular or periocular infection, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO.

Please see additional safety information in the full VABYSMO PI.

